Reports Q1 revenue $1.112M vs $872k last year. “Our first quarter results show accelerating momentum of our business model and the growing market adoption internationally of our non-invasive drug screening technology,” said Harry Simeonidis, President and CEO at Intelligent Bio Solutions (INBS). “We achieved record quarterly revenue of $1.11 million, representing our strongest quarter to date, with 32% growth sequentially and 28% year-over-year. This significant revenue increase, combined with expanding gross margins, validates our strategic focus on consumable cartridge sales and positions us well for sustained growth as we advance along the regulatory pathway toward planned FDA clearance and U.S. market entry.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INBS:
- Intelligent Bio expects to report Q1 revenue growth of 32% sequentially
- Intelligent Bio Solutions Adds 33 New Customer Accounts
- Intelligent Bio Solutions secures 33 customer accounts in Q1
- Intelligent Bio secures major UK contract with industrial service provider
- Intelligent Bio Solutions Approves Incentive Plan Amendment